- Research Methods &
- Research Training
- Research Into
|Title||Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children's hospitals.|
|Publication Type||Journal Article|
|Year of Publication||2019|
|Authors||Bamat NA, Kirpalani H, Feudtner C, Jensen EA, Laughon MM, Zhang H, Monk HM, Passarella M, Lorch SA|
|Date Published||2019 Jun 21|
OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD.
STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children's hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use.
RESULTS: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17-45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22-50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD.
CONCLUSIONS: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center.
|Alternate Journal||J Perinatol|
|Grant List||2T32HD060550-06 / / U.S. Department of Health & Human Services | National Institutes of Health (NIH) / |
K23HL136843 / / U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) /